Ken Griffin Eq Rx, Inc. Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 14, 2023	BUY	$1.66 - $2.31 $186,916 - $260,106	112,600 Added 2447.83%	117,200 $260,000
Q2 2023 Aug 14, 2023	SELL	$1.61 - $1.96 $36,547 - $44,492	-22,700 Reduced 83.15%	4,600 $8,000
Q1 2023 May 15, 2023	SELL	$1.8 - $2.83 $2,520 - $3,962	-1,400 Reduced 4.88%	27,300 $52,000
Q4 2022 Feb 14, 2023	BUY	$2.05 - $5.5 $37,105 - $99,550	18,100 Added 170.75%	28,700 $70,000
Q3 2022 Nov 14, 2022	SELL	$0.94 - $5.99 $52,358 - $333,643	-55,700 Reduced 84.01%	10,600 $52,000

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.